Healthcare technology company, PicnicHealth unveiled a clinical services offering that features a virtual clinic designed for patients and a virtual site targeting life sciences organizations.
The aim of the two services is to improve care management and stimulate more effective observational research.
The virtual clinic gives patients access to the company’s universal patient record system as well as clinician-guided support designed to help them manage their health more efficiently.
With the universal patient record, curated by PicnicHealth’s proprietary AI technology, the company’s clinical care team can evaluate patient histories, recognize care gaps and come up with actionable insights for patients.
In addition, the virtual clinic permits patients to directly interact with the company’s clinical care team where they can actively talk about care recommendations and help with care follow up.
Meanwhile, PicnicHealth’s virtual site allows life science companies to streamline observational research by looking at a broader range of study designs with fresh data collection methods.
For example, the Virtual Site expands upon the company’s status in medical record synthesis by unlocking the capacity to obtain endpoints not recorded during routine care.
The virtual site is backed by a study team of in-house clinicians and principal investigators to guarantee appropriate study conduct.
“We’ve seen how difficult it is to manage complex care journeys, and have designed the virtual clinic to simplify care through a combination of expert clinical guidance and technology,” Dr. Dan Drozd, chief medical officer at PicnicHealth, said in a statement.
“The virtual clinic offers a more cohesive and supportive care experience, ensuring no part of a patient’s care is overlooked.”
THE LARGER TREND
In 2023, PicnicHealth joined forces with AstraZeneca, to establish a registry to generate real-world data utilizing patient medical records to research stage 1 to 3 breast cancer.
That same year, PicnicHealth partnered with Roche subsidiary Genentech, to accelerate neurological disease research through investments in real-world data for Alzheimer’s Disease and Alzheimer’s Disease-related dementias and myasthenia gravis.
